{
    "id": 3289,
    "fullName": "EGFR L861R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L861R lies within the protein kinase domain of the Egfr protein (UniProt.org). L861R results in increased Egfr autophosphorylation and downstream signaling in cell culture (PMID: 24743239) and induces cell proliferation and cell viability in culture (PMID: 29533785).",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3812,
                    "pubMedId": 24743239,
                    "title": "Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24743239"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L861R",
    "createDate": "02/21/2015",
    "updateDate": "04/16/2018",
    "referenceTranscriptCoordinates": {
        "id": 135773,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55191831T>G",
        "cDna": "c.2582T>G",
        "protein": "p.L861R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19055,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in disease progression after 2 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR L861R (PMID: 21841502).",
            "molecularProfile": {
                "id": 3105,
                "profileName": "EGFR L861R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16690,
                    "pubMedId": 21841502,
                    "title": "Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21841502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16727,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L861R were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 3105,
                "profileName": "EGFR L861R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16728,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L861R were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 3105,
                "profileName": "EGFR L861R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18974,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 32732,
                "profileName": "EGFR G719A EGFR L861R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18972,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR G719A and EGFR L861R in cis demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 32732,
                "profileName": "EGFR G719A EGFR L861R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18973,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR G719A and EGFR L861R in cis and trans in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 32732,
                "profileName": "EGFR G719A EGFR L861R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18971,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR G719A and EGFR L861R in cis demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 32732,
                "profileName": "EGFR G719A EGFR L861R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17651,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Tarceva (erlotinib) treatment resulted in a partial response with a progression-free survival of 6 months in a patient with non-small cell lung cancer harboring both EGFR G719A and EGFR L861R (PMID: 31175009).",
            "molecularProfile": {
                "id": 32732,
                "profileName": "EGFR G719A EGFR L861R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15702,
                    "pubMedId": 31175009,
                    "title": "Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31175009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3105,
            "profileName": "EGFR L861R",
            "profileTreatmentApproaches": [
                {
                    "id": 4709,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR L861R"
                },
                {
                    "id": 4710,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR L861R"
                },
                {
                    "id": 4712,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR L861R"
                },
                {
                    "id": 4711,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR L861R"
                },
                {
                    "id": 4708,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR L861R"
                }
            ]
        },
        {
            "id": 32732,
            "profileName": "EGFR G719A EGFR L861R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135773,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55191831T>G",
            "cDna": "c.2582T>G",
            "protein": "p.L861R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}